{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000457","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.410729+00:00","generated_at":"2026-05-27T08:24:14.870196+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BeyondSpring sells SEED Therapeutics stake for $35.4M to fund Plinabulin trials","bullets":["Sells 8,333,637 Series A-1 Preferred Shares at $4.25/share to three investors for ~$35.4M gross proceeds.","After all closings, BeyondSpring and subsidiary will own ~14.4% of SEED (down from ~41% initially).","Proceeds advance Plinabulin to registrational studies; DUBLIN-3 showed OS benefit in NSCLC.","303 study of Plinabulin + pembrolizumab/docetaxel achieved 89.3% DCR and 8.6 mo median PFS.","302 study enrolling first-line ES-SCLC patients; Plinabulin has GEF-H1 immune activation mechanism."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000457","json":"https://secwatch.observer/filing/0001171843-25-000457.json","markdown":"https://secwatch.observer/filing/0001171843-25-000457.md","text":"https://secwatch.observer/filing/0001171843-25-000457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325000457/0001171843-25-000457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325000457/f8k_012725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:24:14.870196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}